Next Science

Next Science ROCE

Delisted

The Return on Capital Employed (ROCE) of Next Science (NXS.AX) as of Oct 29, 2026 is -296.90 %. In the previous year, Return on Capital Employed (ROCE) was -124.23 % — a change of 139.00% (lower).

ROCE

-296.90 %

YoY

139.00%

Last updated:

In 2024, Next Science's return on capital employed (ROCE) was -296.90 %, a 139.00% increase from the -124.23 % ROCE in the previous year.

The Next Science ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2017
-85.28 USD
Jan 1, 2018
-3,421.12 USD
Jan 1, 2019
-64.56 USD
Jan 1, 2020
-66.05 USD
Jan 1, 2021
-89.08 USD
Jan 1, 2022
-157.51 USD
Jan 1, 2023
-124.23 USD
Jan 1, 2024
-296.90 USD
The Next Science ROCE history
YEARROCEYoY
-296.90 %+139.00%
-124.23 %-21.13%
-157.51 %+76.82%
-89.08 %+34.86%
-66.05 %+2.31%
-64.56 %-98.11%
-3,421.12 %+3,911.42%
-85.28 %-54.29%
-186.57 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Next Science Stock analysis

What does Next Science do? Next Science Ltd. generates revenue through the development and commercialization of its XBIO technology, which addresses bacterial biofilm-related infections in human health. The company's product portfolio includes XPERIENCE, a solution for preventing surgical site infections by rinsing away debris and microorganisms, and SurgX Sterile Antimicrobial Gel, designed to reduce surgical and post-surgical infections through sustained antibacterial action for up to five days. Blast X, an antimicrobial wound gel, targets bacterial infections in wounds. These products are sold to healthcare providers and medical facilities seeking effective solutions for bacterial biofilm eradication and infection prevention. The XBIO technology underpins all products, offering non-toxic efficacy against both biofilm and free-floating bacteria. XPERIENCE is used as a pre-surgical rinse, SurgX provides prolonged protection post-surgery, and Blast X treats existing wounds. Healthcare institutions, particularly hospitals and surgical centers, are the primary buyers, leveraging these products to enhance patient outcomes and reduce infection rates. Next Science Ltd. focuses on the healthcare sector, specifically targeting applications where bacterial biofilms pose significant risks. The company's products are positioned for use in surgical settings, wound care, and infection prevention protocols. By addressing critical needs in medical environments, the firm caters to healthcare providers who prioritize non-toxic, effective antimicrobial solutions for patient safety and operational efficiency. Next Science is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Next Science's Return on Capital Employed (ROCE)

Next Science's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Next Science's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Next Science's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Next Science’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Next Science stock

Return on Capital Employed (ROCE) of Next Science is -296.90 % in 2024.

Return on Capital Employed (ROCE) of Next Science changed from -124.23 % to -296.90 %, representing a 139.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Next Science since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Next Science with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Next Science

All Key Metrics — Next Science